BridgeBio Pharma : BBIO – Encaleret – ADH1 – ENDO 2025 – Phase 2 Over 42 Months Data Results
BBIO
Published on 07/14/2025 at 17:43
1. NIDCR, NIH, Bethesda, MD, USA; 2. MetisMedica, Toronto, ON, Canada; 3. BridgeBio Pharma, Inc. affiliate Calcilytix Therapeutics, Inc, San Francisco, CA, USA; 4. Advisor/Consultant for Calcilytix Therapeutics, Inc., San Francisco USA
July 14, 2025
Disclosures
This study was supported by a public/private partnership between the NIDCR Intramural Research Program and BridgeBio affiliate Calcilytix Therapeutics, Inc.
Encaleret is currently under clinical development, and its safety and
efficacy have not been evaluated by any regulatory authority.
The views expressed in this educational program are those of the faculty and do not necessarily represent the views of the Endocrine Society
2
Blood calcium is maintained by four organs regulated by the CaSR and PTH
Activating variants in the CASR
increase tissue sensitivity to Ca2+
Hypersensitive CaSR causes dysregulation of Ca homeostasis
Clinical Manifestations
PTH Secretion
Parathyroid
Kidney
Wild
Type
ADH1
Blood Ca2+
ADH1
Wild
Type
Blood Ca2+
Decreased PTH secretion
Ca2+
PTH
Decreased blood calcium
Ca2+
Ca2+ Excretion
Increased urinary calcium
Tetany Muscle cramps
Conventional therapy with calcium and activated vitamin D does not correct the underlying pathophysiology and has the potential to worsen long-term complications
Chronic Kidney Disease
PTH Secretion
Encaleret is an investigational negative allosteric modulator of the CaSR that can decrease CaSR sensitivity to extracellular calcium
Normalizing CaSR sensitivity could correct hypocalcemia, hypercalciuria, and low PTH in individuals with ADH1
Parathyroid Kidney
ADH1
Wild type
Calcilytic
ADH1
Wild type
Calcilytic
Ca2+ Excretion
Blood Ca2+ Blood Ca2+
Disclaimer
BridgeBio Pharma Inc. published this content on July 14, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on July 14, 2025 at 21:42 UTC.